New York, Aug. 18 - Natus Medical Inc. priced a $26.75 million follow-on offering of common stock after the close Thursday at $11.63 per share, in line with the day's closing price.
The company sold a total of 2.3 million shares. There is a greenshoe for a further 345,000 shares.
D3 Family Fund LP, D3 Family Bulldog Fund LP and D3 Offshore Fund LP bought 350,000 of the shares. No underwriting commissions were paid on this part of the sale.
Roth Capital Partners was underwriter for the offering, which was sold off Natus' shelf.
Natus will use proceeds for general corporate purposes, which may include acquisitions, capital expenditures or additions to working capital. The company said it may also use part of the proceeds to repay the $7.5 million outstanding on its senior secured credit facility with Wells Fargo Bank.
Natus is a San Carlos, Calif., provider of health care products used for screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, newborn jaundice and newborn metabolic testing.
| Issuer: | Natus Medical Inc.
|
| Issue: | Follow-on offering of common stock
|
| Amount: | $26.749 million
|
| Shares: | 2.3 million
|
| Greenshoe: | 345,000
|
| Price: | $11.63
|
| Pricing date: | Aug. 17, after close
|
| Settlement date: | Aug. 23
|
| Underwriter: | Roth Capital Partners
|
| Stock symbol: | Nasdaq: BABY
|
| Stock price: | $11.63 at close Aug. 17
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
